Research programme: immune checkpoint inhibitors - Innate Pharma

Drug Profile

Research programme: immune checkpoint inhibitors - Innate Pharma

Alternative Names: anti-CD73 antibodies; IPH 53

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Paoli-Calmettes-institute
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data from preclinical studies in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2018)
  • 15 Mar 2018 Preclinical trials in Cancer in France (unspecified route)
  • 06 Jul 2015 Innate Pharma and Paoli Calmettes Institute collaborate on translational research for immune checkpoint inhibitor antibodies for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top